Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.58 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434587 | 0.94 | ECE1 (0.52) | ECE1PDCD1LG2CD274CTSCITGB2 | |
| SCHEMBL29630705 | 0.94 | ECE1 (0.52) | ECE1PDCD1LG2CD274CTSCITGB2 | |
| SCHEMBL29630757 | 0.94 | ECE1 (0.52) | ECE1PDCD1LG2CD274CTSCITGB2 | |
| SCHEMBL29630570 | 0.94 | ECE1 (0.52) | ECE1PDCD1LG2CD274CTSCITGB2 | |
| SCHEMBL29630814 | 0.92 | ECE1 (0.51) | ECE1PDCD1LG2CD274CTSCVSIR | |
| SCHEMBL29870994 | 0.92 | ECE1 (0.51) | ECE1PDCD1LG2CD274CTSCMME | |
| SCHEMBL29630710 | 0.91 | ECE1 (0.54) | ECE1PDCD1LG2CD274 | |
| SCHEMBL29630884 | 0.91 | ECE1 (0.54) | ECE1PDCD1LG2CD274 | |
| SCHEMBL29630775 | 0.91 | ECE1 (0.54) | ECE1PDCD1LG2CD274 | |
| SCHEMBL29630874 | 0.91 | ECE1 (0.54) | ECE1PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118217402-A | Combination therapy for C3 inhibition | 阿佩利斯制药有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-4385516-A1 | SYNTHETIC PEPTIDE, AND COSMETIC COMPOSITION OR PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shenzhen Winkey Technology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | claimed |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | claimed |
| EP-4105224-A1 | LONG-ACTING COMPSTATIN ANALOGS AND USES THEREOF | Apellis Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| US-20220289846-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-09-15 | — | — | US | claimed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | claimed |
| EP-3997126-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-18 | — | — | EP | claimed |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12516121-B2 | Antibodies to human programmed death receptor PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2026-01-06 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12448425-B2 | Therapeutic peptides | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3524258-B1 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS | APELLIS PHARMACEUTICALS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| CN-105582523-B | Compstatin and analogs thereof for ocular disorders | 阿佩利斯制药公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11291407-B2 | Detection of high risk drusen | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2022061304-A1 | METHODS OF TREATING EYE DISORDERS | APELLIS PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| EP-3966567-A1 | THERAPEUTIC PEPTIDES | Board of Regents, The University of Texas System (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-110819608-B | Hydrolysis method of zearalenone and derivatives thereof | 湖北大学 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | EXOSC4, EXOSC5, EXOSC10 | ECE1 92/4885PDCD1LG2 1221/4885CD274 939/4885 |
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | ECE1 202/4885PDCD1LG2 3008/4885CD274 2912/4885 |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | ECE1 251/4885PDCD1LG2 3329/4885CD274 3422/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | ECE1 308/4885PDCD1LG2 1969/4885CD274 2496/4885 |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, ADAM8, MSTN | ECE1 34/4885PDCD1LG2 4474/4885CD274 4684/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | ECE1 830/4885PDCD1LG2 1734/4885CD274 1291/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | ECE1 259/4885PDCD1LG2 3364/4885CD274 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.